Akeega Approved for BRCA2-Mutated Prostate Cancer

By News Health
3 weeks Ago

(MedPage Today) — The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on Friday.
The once-daily, fixed…

Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/119017

Author :

Publish date : 2025-12-15 19:12:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Brain Stimulation Matches Semaglutide for Weight Loss

People coming off weight-loss injections risk fast weight gain

Exercise may relieve depression as effectively as antidepressants

Common Food Additive Linked to Cancer Risk

Health Gains Vanish Within 2 Years of Stopping Weight-Loss Drugs

Why my period made my gambling addiction worse